Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Gonzalo Bentolila & Astrid Pavlovsky. (2020) Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation. Leukemia & Lymphoma 61:7, pages 1548-1554.
Read now
Read now
Hervé Ghesquières, Aspasia Stamatoullas, Olivier Casasnovas, Franck Morschhauser, Emmanuel Gyan, Jean Gabarre, Marion Malphettes, Laurence Clément, Céline Ferlay & Pauline Brice. (2013) Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leukemia & Lymphoma 54:11, pages 2399-2404.
Read now
Read now
Bastian von Tresckow & Andreas Engert. (2012) The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant. Expert Review of Hematology 5:5, pages 483-486.
Read now
Read now
Martin Hutchings. (2011) Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients?. Leukemia & Lymphoma 52:9, pages 1615-1616.
Read now
Read now
Articles from other publishers (46)
Eleonora Calabretta, Martina di Trani, Francesco Corrado, Martina Sollini, Vanessa Cristaldi, Fabrizio Marino, Lodovico Terzi di Bergamo, Alessio Bruscaggin, Maria Cristina Pirosa, Stefania Bramanti, Arturo Chiti, Davide Rossi & Carmelo Carlo‐Stella. (2023)
Baseline circulating tumour
DNA
and interim
PET
predict response in relapsed/refractory classical Hodgkin lymphoma
. British Journal of Haematology.
Crossref
Crossref
Locke J. Bryan, Carla Casulo, Pamela B. Allen, Scott E. Smith, Hatice Savas, Gary L. Dillehay, Reem Karmali, Barbara Pro, Kaitlyn L. Kane, Latifa A. Bazzi, Joan S. Chmiel, Brett A. Palmer, Jayesh Mehta, Leo I. Gordon & Jane N. Winter. (2023) Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma. JAMA Oncology 9:5, pages 683.
Crossref
Crossref
Alison J. Moskowitz. (2022) Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?. Hematology 2022:1, pages 699-705.
Crossref
Crossref
Ho‐Young Yhim, Yael Eshet, Ur Metser, Katherine Lajkosz, Matthew Cooper, Anca Prica, Vishal Kukreti, Sita Bhella, Noémie Lang, Wei Xu, Danielle Rodin, David Hodgson, Richard Tsang, Michael Crump, John Kuruvilla & Robert Kridel. (2022) Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. American Journal of Hematology 97:5, pages 583-591.
Crossref
Crossref
Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, Horst Müller, Annette Plütschow, Andreas Viardot, Max S. Topp, Carsten Kobe, Boris Böll, Dennis A. Eichenauer, Stephanie Sasse, Heinz Haverkamp, Christine Schmitz, Sven Borchmann, Paul J. Bröckelmann, Jan‐Michel Heger, Michael Fuchs, Andreas Engert, Peter Borchmann & Bastian von Tresckow. (2021) Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i). British Journal of Haematology 196:3, pages 606-616.
Crossref
Crossref
Alison J. Moskowitz, Gunjan Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Samia Sohail, Alayna Santarosa, Natasha Galasso, Rachel Neuman, Brielle Liotta, William Blouin, Anita Kumar, Oscar Lahoud, Connie L. Batlevi, Paul Hamlin, David J. Straus, Ildefonso Rodriguez-Rivera, Colette Owens, Philip Caron, Andrew M. Intlekofer, Audrey Hamilton, Steven M. Horwitz, Lorenzo Falchi, Erel Joffe, William Johnson, Christina Lee, M. Lia Palomba, Ariela Noy, Matthew J. Matasar, Georgios Pongas, Gilles Salles, Santosha Vardhana, Beatriz Wills Sanin, Gottfried von Keudell, Joachim Yahalom, Ahmet Dogan, Andrew D. Zelenetz & Craig H. Moskowitz. (2021) Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Journal of Clinical Oncology 39:28, pages 3109-3117.
Crossref
Crossref
Heather A. Jacene. (2021) FDG PET for Assessment of Autologous Stem Cell Transplantation. Seminars in Nuclear Medicine 51:4, pages 380-391.
Crossref
Crossref
Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio ChavezYago Nieto, Justin M. DarrahUttam RaoMichael T. ByrneDavid A. Bond, Kami J. MaddocksMichael A. SpinnerRanjana H. AdvaniHatcher J. BallardJakub SvobodaAnurag K. SinghJoseph P. McGuirk, Dipenkumar Modi, Radhakrishnan RamchandrenJason Romancik, Jonathon B. Cohen, Matthew J. FrigaultYi-Bin ChenAnthony V. SerritellaJustine KlineStephen AnsellSunita NathanMaryam RahimianRobin M. Joyce, Mansi Shah, Kevin A. DavidSteven Park, Anne W. BeavenAlma HabibVeronika BachanovaShazia Nakhoda, Nadia Khan, Ryan C. Lynch, Stephen D. Smith, Vincent T. Ho, Ann LaCasce, Philippe Armand & Alex F. Herrera. (2021) Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Advances 5:6, pages 1648-1659.
Crossref
Crossref
Richard T. HoppeRanjana H. AdvaniWeiyun Z. AiRichard F. AmbinderPhilippe ArmandCeleste M. BelloCecil M. BenitezPhilip J. BiermanKirsten M. BoughanBouthaina DabajaLeo I. GordonFrancisco J. Hernandez-IlizaliturriAlex F. HerreraEphraim P. HochbergJiayi HuangPatrick B. JohnstonMark S. KaminskiVaishalee P. KenkreNadia KhanRyan C. LynchKami MaddocksJonathan McConathyMatthew McKinneyMonika MetzgerDavid MorganCarolyn MulroneyRachel RabinovitchKaren C. RosenspireStuart SeropianRanda TaoJane N. WinterJoachim Yahalom, Jennifer L. BurnsNdiya Ogba. (2020) Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 18:6, pages 755-781.
Crossref
Crossref
Angela Aldin, Lisa Umlauff, Lise J Estcourt, Gary Collins, Karel GM Moons, Andreas Engert, Carsten Kobe, Bastian von Tresckow, Madhuri Haque, Farid Foroutan, Nina Kreuzberger, Marialena Trivella & Nicole Skoetz. (2020) Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database of Systematic Reviews 2020:8.
Crossref
Crossref
Nancy Bartlett & Grace Triska. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1911
1925.e3
.
Paul J. Bröckelmann & Lena Specht. 2020. Hodgkin Lymphoma. Hodgkin Lymphoma
145
169
.
Andrea Gallamini, Bruce Cheson & Martin Hutchings. 2020. Hodgkin Lymphoma. Hodgkin Lymphoma
113
143
.
Bastian von Tresckow & Craig Moskowitz. 2020. Hodgkin Lymphoma. Hodgkin Lymphoma
351
363
.
Angela Aldin, Lisa Umlauff, Lise J Estcourt, Gary Collins, Karel GM Moons, Andreas Engert, Carsten Kobe, Bastian von Tresckow, Madhuri Haque, Farid Foroutan, Nina Kreuzberger, Marialena Trivella & Nicole Skoetz. (2019) Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Alison J. Moskowitz, Alex F. Herrera & Anne W. Beaven. (2019) Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy. American Society of Clinical Oncology Educational Book:39, pages 477-486.
Crossref
Crossref
Alessandro Broccoli & Pier Luigi Zinzani. (2019) The role of transplantation in Hodgkin lymphoma. British Journal of Haematology 184:1, pages 93-104.
Crossref
Crossref
Alison J. Moskowitz. (2018) Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy. Hematology 2018:1, pages 207-212.
Crossref
Crossref
Martin Hutchings. (2018) Improvements in Imaging of Hodgkin Lymphoma. The Cancer Journal 24:5, pages 215-222.
Crossref
Crossref
Louis S. Constine, Joachim Yahalom, Andrea K. Ng, David C. Hodgson, Andrew Wirth, Sarah A. Milgrom, N. George Mikhaeel, Hans Theodor Eich, Tim Illidge, Umberto Ricardi, Karin Dieckmann, Craig H. Moskowitz, Ranjana Advani, Peter M. Mauch, Lena Specht & Richard T. Hoppe. (2018) The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology*Biology*Physics 100:5, pages 1100-1118.
Crossref
Crossref
Vít Procházka, Rakhee S. Gawande, Zuzan Cayci, Jerry W. Froelich, Qing Cao, Chris Wilke, Kathryn Dusenbery, Daniel J. Weisdorf & Veronika Bachanova. (2018) Positron Emission Tomography–Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 24:1, pages 64-70.
Crossref
Crossref
Nmazuo W. Ozuah, Hisham M. Dahmoush, Frederick D. Grant, Leslie E. Lehmann, Ann S. LaCasce, Amy L. Billett & Steven P. Margossian. (2018) Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation. Pediatric Blood & Cancer 65:1, pages e26707.
Crossref
Crossref
Alison J. Moskowitz, Heiko SchöderSomali Gavane, Katie L. Thoren, Martin Fleisher, Joachim Yahalom, Susan J. McCall, Briana R. Cadzin, Stephanie Y. Fox, John Gerecitano, Ravinder GrewalPaul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew Matasar, Andy Ni, Ariela Noy, M. Lia Palomba, Miguel-Angel Perales, Carol S. Portlock, Craig Sauter, David Straus, Anas Younes, Andrew D. Zelenetz & Craig H. Moskowitz. (2017) Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood 130:20, pages 2196-2203.
Crossref
Crossref
M Damlaj, S Ghazi, G Syed, T Pasha, G Gmati, H Salama, O Ali, K A Abuelgasim, M Al-Zahrani, A Hejazi & A Al Askar. (2017) Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplantation 52:9, pages 1342-1344.
Crossref
Crossref
Niloufer Khan & Alison J. Moskowitz. (2017) Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?. Current Hematologic Malignancy Reports 12:3, pages 227-233.
Crossref
Crossref
Mateen C. Moghbel, Erik Mittra, Andrea Gallamini, Ryan Niederkohr, Delphine L. Chen, Katherine Zukotynski, Helen Nadel & Lale Kostakoglu. (2017) Response Assessment Criteria and Their Applications in Lymphoma: Part 2. Journal of Nuclear Medicine 58:1, pages 13-22.
Crossref
Crossref
M. Ladetto, C. Buske, M. Hutchings, M. Dreyling, G. Gaidano, S. Le Gouill, S. Luminari, C. Pott, A. Zamò, E. Zucca, C. Buske, M. Dreyling, A.J.M. Ferreri, P. Fields, G. Gaidano, V. Goede, M. Hutchings, M. Ladetto, S.L. Gouill, S. Luminari, U. Mey, P.d.N. Brown, M. Pfreundschuh, C. Pott, N. Schmitz, P. Soubeyran, M. Spina, R. Stauder, A.S. Balari, M. Trněný, G.v. Imhoff, J. Walewski, U. Wedding, A. Zamò & E. Zucca. (2016) ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Annals of Oncology 27:12, pages 2149-2160.
Crossref
Crossref
Gunjan L. Shah, Joachim Yahalom, Matthew J. Matasar, Stephanie L. Verwys, Debra A. Goldman, Kurt S. Bantilan, Zhigang Zhang, Susan J. McCall, Alison J. Moskowitz & Craig H. Moskowitz. (2016) Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. British Journal of Haematology 175:3, pages 440-447.
Crossref
Crossref
Chen Wang, Panli Li, Shan Wu, Jianda Lu, Qiufang Liu, Huajie Luo & Shaoli Song. (2016) The role of fluorine-18 fluorodeoxyglucose PET in prognosis evaluation for stem cell transplantation of lymphoma. Nuclear Medicine Communications 37:4, pages 338-347.
Crossref
Crossref
Hugo J. A. Adams & Thomas C. Kwee. (2016) Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Annals of Hematology 95:5, pages 695-706.
Crossref
Crossref
IGNACIO GARCÍA ESCOBAR, ANA LÓPEZ, JUDIT RUBIO, DAVID PÉREZ-CALLEJO, DOLORES CABALLERO BARRIGÓN, PILAR TAMAYO ALONSO, ELENA ALMAGRO CASADO & MARIANO PROVENCIO PULLA. (2016) Clinical pretreatment risk factors and prediction of outcome using gallium 67 scintigraphy in patients with Hodgkin's lymphoma. Molecular and Clinical Oncology 4:1, pages 93-99.
Crossref
Crossref
Martin Hutchings, Miguel A. Piris, Otavio Baiocchi & Mark Hertzberg. (2015) Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Cancer Treatment Communications 4, pages S1-S11.
Crossref
Crossref
Martin Hutchings & Sally Barrington. (2015) FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. Clinical and Translational Imaging 3:4, pages 271-281.
Crossref
Crossref
Miguel-Angel Perales, Izaskun Ceberio, Philippe Armand, Linda J. Burns, Robert Chen, Peter D. Cole, Andrew M. Evens, Ginna G. Laport, Craig H. Moskowitz, Uday Popat, Nishitha M. Reddy, Thomas C. Shea, Julie M. Vose, Jeffrey Schriber, Bipin N. Savani & Paul A. Carpenter. (2015) Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 21:6, pages 971-983.
Crossref
Crossref
Alison J Moskowitz, Heiko Schöder, Joachim Yahalom, Susan J McCall, Stephanie Y Fox, John Gerecitano, Ravinder Grewal, Paul A Hamlin, Steven Horwitz, Rachel Kobos, Anita Kumar, Matthew Matasar, Ariela Noy, M Lia Palomba, Miguel-Angel Perales, Carol S Portlock, Craig Sauter, Neerav Shukla, Peter Steinherz, David Straus, Tanya Trippett, Anas Younes, Andrew Zelenetz & Craig H Moskowitz. (2015) PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. The Lancet Oncology 16:3, pages 284-292.
Crossref
Crossref
Lena Specht & Dirk Hasenclever. 2015. Hodgkin Lymphoma. Hodgkin Lymphoma
131
155
.
Bastian von Tresckow & Craig Moskowitz. 2015. Hodgkin Lymphoma. Hodgkin Lymphoma
321
330
.
Sally Fiona Barrington & Nabegh George Mikhaeel. (2014) When should FDG-PET be used in the modern management of lymphoma?. British Journal of Haematology 164:3, pages 315-328.
Crossref
Crossref
Martin Hutchings. (2014) FDG-PET Response–adapted Therapy. Hematology/Oncology Clinics of North America 28:1, pages 87-103.
Crossref
Crossref
Mark Hertzberg. (2014) Relapsed/Refractory Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:1, pages 123-147.
Crossref
Crossref
Nancy L. Bartlett & Kelley V. Foyil. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
2018
2032.e4
.
S Akhtar, A S Al-Sugair, M Abouzied, Y AlKadhi, M Dingle, M Abdelsalam, H Soudy, A Darwish, A Eltigani, T A M Elhassan, M Nabil-Ahmed & I Maghfoor. (2013) Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplantation 48:12, pages 1530-1536.
Crossref
Crossref
Renaud GuignardColette Zwarthoed, Anna Borra, Jacques Darcourt & Andrea Gallamini. (2013) PET scan integration in lymphoma management. International Journal of Hematologic Oncology 2:2, pages 121-135.
Crossref
Crossref
Martin Hutchings. (2012) How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. Hematology 2012:1, pages 322-327.
Crossref
Crossref
Young Wha Koh, Hyo Jeong Kang, Chansik Park, Dok Hyun Yoon, Shin Kim, Cheolwon Suh, Ji Eun Kim, Chul-Woo Kim & Jooryung Huh. (2012) Prognostic Significance of the Ratio of Absolute Neutrophil Count to Absolute Lymphocyte Count in Classic Hodgkin Lymphoma. American Journal of Clinical Pathology 138:6, pages 846-854.
Crossref
Crossref
Oguz Akin, Sandra B. Brennan, D. David Dershaw, Michelle S. Ginsberg, Marc J. Gollub, Heiko Schöder, David M. Panicek & Hedvig Hricak. (2012) Advances in oncologic imaging. CA: A Cancer Journal for Clinicians 62:6, pages 364-393.
Crossref
Crossref